The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
-
Phoenix Children's Hospital, Phoenix, Arizona, United States, 85016
Children's Hospital of Orange County, Orange, California, United States, 92868
University of California, San Diego, California, United States, 92123
Yale School of Medicine, New Haven, Connecticut, United States, 06510
George Washington University School of Medicine, Washington, District of Columbia, United States, 20010
University of Miami, Miami, Florida, United States, 33136
Miami Children's Hospital, Miami, Florida, United States, 33155
All Children's Hospital, Saint Petersburg, Florida, United States, 33701
Children's Memorial Hospital, Chicago, Illinois, United States, 60614
Indiana University School of Medicine, Indianapolis, Indiana, United States, 46202
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to 20 Years
ALL
No
Washington University School of Medicine,
Shalini Shenoy, MD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine (in St. Louis)
2031-12